Bio21 Symposium in Honour of Professor Frances Separovic AO

Monday, 30 September, 2019 - 13:00 to 17:00

The symposium will take place at the Bio21 Molecular Science and Biotechnology Institute, Monday, 30 September, 1-5pm


Media Release: CSL to Move Global Headquarters to Parkville Biomedical Precinct

Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination

Bio21 Methods Symposium: Emerging Technologies for New Challenges - 24 October 2019

Thursday, 24 October, 2019 - 09:00 to 17:30

Learn about the latest methods and technologies being used to address today’s fundamental biological questions.

CryoEM insights into the nanomachine that powers the cell’s garbage disposal system

Capitalising on the revolution brought about by structural cryo-electron microscopy (cryo-EM), a Bio21 team led by Dr Mike Griffin and Prof Leann Tilley has generated molecular movies of a sophisticated nano-machine, called the proteasome. 

Professor Karen Day receives US$3 million NIH funding to pursue world-leading malaria research

Professor Karen Day has secured almost US$3 million funding from the NIH to further her world-leading malaria research at the Bio21 Institute.

Pursuit: Using bacteria to control mosquitoes

Read Bio21's Ary Hoffmann's piece published in Pursuit about how the Wolbachia bateria may hold the key to controlling the spread of dengue fever, the Zika virus and other mosquito-borne diseases.

When an artist looks at a chemical element, what do they see?

Art meets Science in this new exhibition at Quantum Victoria by artists Damon Kowarsky and Hyunju Kim's displaying artworks with a unique interpretation of the periodic table of chemical elements. Read this piece by Professor Frances Separovic published in The Conversation.

Women of Bio21 - Ineke Muir

Ineke Muir heads the Vascular Biophysics team, CSL Research. She investigates the effects of shear forces on preclinical drugs and therapies, to predict how they will behave in the bloodstream. She’s also a mum, an avid bike rider and an occasional bookworm.

Media Release: Researchers discover why patients develop resistance to commonly-used cancer drug

Michael Parker and Craig Morton, St Vincent’s Institute of Medical Research (SVI) in Melbourne Australia, and Bio21 Institute are part of an international team of collaborators that has made a discovery that may lead to more effective treatment and less side effects for a number of cancers including neuroblastoma, a cancer that occurs most commonly in infants and children under 5 years of age.

Lightning strikes twice for potential Parkinson’s disease and MND drug

A phase 1 human clinical trial of a compound developed by Paul Donnelly, School of Chemistry and Kevin Barnham (Florey Institute of Neuroscience and Mental Health) whilst at the Bio21 Molecular Science and Biotechnology Institute and Anthony White, University of Melbourne and is showing promise in alleviating the symptoms of Parkinson’s disease.


Subscribe to Bio21 Molecular Science & Biotechnology Institute RSS